[Click eStock] "Eutilex, Attractive Pipeline"

[Asia Economy Reporter Hyungsoo Park] KB Securities analyzed on the 25th that the three pipeline clinical trials of Eutilex are progressing smoothly.

Eutilex is developing immuno-oncology drugs including antibody therapeutics, T-cell therapeutics, chimeric antigen receptor T-cell (CAR-T) therapeutics, and allogenic T-cell therapeutics.

Researcher Im from KB Securities explained, "Phase 1/2 clinical trials for EU101 are underway in Korea and the United States," and added, "As an immune checkpoint activator specialized in T-cell activation and proliferation, high growth potential is expected in the future."

He continued, "BMS and Pfizer have also developed 4-1BB targeting antibody therapeutics," but "clinical trials were discontinued due to liver toxicity issues and failure to prove efficacy."

Furthermore, he emphasized, "Eutilex resolved toxicity issues through engineered IgG1 (immunoglobulin)," and "there have been no cases of toxicity or side effects so far."

Researcher Im analyzed, "Recently, excellent therapeutic effects are expected through low-dose administration," and "significant synergy and therapeutic effects are anticipated when combined with immune checkpoint inhibitors such as Keytruda."

He said, "Value increase is expected through early commercialization and as an innovative drug following the Phase 2 clinical trial of EU204 (AbbVNT)," and "in the case of lymphoma, complete remission was observed in investigator-initiated clinical trials and Phase 1/2a trials."

He added, "We expect the growth potential of EU307, a CAR-T therapeutic targeting solid tumors that overcomes the limitations of existing CAR-T cell therapies," and introduced, "EU307 is a next-generation CAR-T cell therapeutic targeting GPC3, which is highly expressed in liver cancer among solid tumors." Eutilex induces immune activation in GPC3 CAR-T cells targeting liver cancer and enhanced anticancer effects by attaching IL-18 receptor, a type of cytokine that extends the maintenance period of CAR-T cell therapeutics in the body.